Edition:
United States

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

2.33CAD
12:00pm EDT
Change (% chg)

$0.09 (+4.02%)
Prev Close
$2.24
Open
$2.34
Day's High
$2.40
Day's Low
$2.31
Volume
1,093,769
Avg. Vol
2,273,597
52-wk High
$3.49
52-wk Low
$1.47

Latest Key Developments (Source: Significant Developments)

Prometic Life Sciences Inc entered into a binding memorandum of terms with Shenzhen Royal Asset Management
7:00am EDT 

Prometic Life Sciences Inc : Prometic Life Sciences Inc - entered into a binding memorandum of terms with Shenzhen Royal Asset Management to establish a joint venture . Prometic Life Sciences Inc - prometic to own 75pct of joint venture following SRAM'S $33 million investment . Prometic Life Sciences - to establish JV for development, manufacture and commercialization of PBI-4050, PBI-4547 and PBI-4425 in China . Prometic Life Sciences - SRAM will provide $23 million in 2017, to secure an initial 17pct ownership of prometic chinaco .Prometic Life Sciences Inc - SRAM will have right to increase ownership in prometic chinaco to up to 25pct with further $10 million investment.  Full Article

Prometic enters into binding agreement to secure $25 million follow-on financing from structured Alpha LP
Friday, 24 Mar 2017 06:30am EDT 

Prometic Life Sciences Inc : Prometic enters into binding agreement to secure $25 million follow-on financing from structured Alpha LP, an affiliate of Thomvest Asset Management Inc . Prometic Life Sciences Inc - $25 million debt financing to bear interest of 8.5pct per annum and repayable in July, 2022 . Prometic Life Sciences Inc - proceeds received by prometic from aggregate exercise of all of warrants would be sufficient to repay loan in its entirety .Prometic Life Sciences -as partial consideration for loan, co will grant structured Alpha LP 10.6 million warrants with an exercise price of $3.70 per share.  Full Article

Prometic says FDA grants orphan drug designation to its PBI-4050 drug
Friday, 3 Mar 2017 06:30am EST 

Prometic Life Sciences Inc : US FDA grants orphan drug designation to Prometic's PBI-4050 drug for the treatment of alström syndrome .Prometic Life Sciences - currently investigating effects of PBI-4050 on multiple organs in as patients in ongoing, open label, phase 2, clinical study in UK.  Full Article

Prometic says PBI-4050 shows encouraging efficacy in IPF study
Wednesday, 22 Feb 2017 06:30am EST 

Prometic Life Sciences Inc : Prometic's PBI-4050 continues to demonstrate early evidence of efficacy following completion of idiopathic pulmonary fibrosis phase 2 clinical trial . Prometic life sciences inc - early evidence of efficacy of pbi-4050 as a monotherapy and in combination with one of commercially available drugs confirmed . Prometic life sciences inc - pbi-4050 continues to be very well tolerated, whether used alone or in combination with nintedanib or pirfenidone .Prometic life sciences inc - intend to initiate in q2 2017 pivotal phase 2/3 ipf clinical trial.  Full Article

ProMetic Life Sciences says California Capital Equity acquires 44 mln of co's shares
Monday, 6 Feb 2017 06:30am EST 

ProMetic Life Sciences Inc : California Capital Equity, LLC acquires 44 million ProMetic shares through the exercise of all outstanding warrants .California Capital Equity has exercised 44.8 million share purchase warrants at price of $0.47 per share for total proceeds of $21.1 million.  Full Article

Prometic reacquires plasminogen rights from Hematech
Thursday, 5 Jan 2017 06:30am EST 

Prometic Life Sciences Inc : Prometic reacquires plasminogen rights from Hematech . Prometic Life Sciences Inc - regains 100 pct ownership of profits from future sales of plasminogen for congenital deficiency . Prometic Life Sciences Inc - hematech continues to hold taiwanese rights to ppps™ as cmo supplier to prometic . Prometic Life Sciences Inc - consideration for acquiring rights included issuance of 1.7 million shares of prometic to Hematech . Prometic Life Sciences Inc - amended its licensing agreement originally entered into with Hematech Biotherapeutics Inc in May 2012 .Prometic Life Sciences Inc - consideration included payment of mid-single digit royalty as well as other non-cash considerations to license agreement.  Full Article

ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial
Thursday, 17 Nov 2016 07:24am EST 

ProMetic Life Sciences Inc :ProMetic's PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial.  Full Article

Prometic's PBI-4050 demonstrates early evidence of efficacy in its IPF Phase 2 clinical trial
Thursday, 17 Nov 2016 06:30am EST 

Prometic Life Sciences Inc - : Early evidence of efficacy of PBI-4050 alone and also in combination with one of commercially available IPF drugs . PBI-4050 shown to be very well tolerated whether used alone or in combination with nintedanib or pirfenidone .4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial.  Full Article

Prometic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial
Wednesday, 16 Nov 2016 06:30am EST 

Prometic Life Sciences Inc : Says phase 2 clinical trial on pbi-4050 expected to commence in Q4 2016 .Prometic receives clearance from Health Canada to proceed with its PBI-4050 placebo-controlled phase 2 clinical trial in patients with metabolic syndrome and type 2 diabetes.  Full Article

Prometic announces closing of Telesta Therapeutics acquisition
Monday, 31 Oct 2016 08:59am EDT 

Prometic Life Sciences Inc :Prometic announces closing of Telesta Therapeutics Inc Acquisition.  Full Article

More From Around the Web

BRIEF-ProMetic's PBI-4050 Demonstrates Early Evidence of Efficacy in its Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial

* ProMetic's PBI-4050 demonstrates early evidence of efficacy in its idiopathic pulmonary fibrosis ("IPF") phase 2 clinical trial Source text for Eikon: Further company coverage: